<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112682</url>
  </required_header>
  <id_info>
    <org_study_id>BOOG 2013-07</org_study_id>
    <secondary_id>KWF UM 2013-5920</secondary_id>
    <nct_id>NCT02112682</nct_id>
  </id_info>
  <brief_title>Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy</brief_title>
  <official_title>The Value of Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy. A Dutch Randomized Controlled Multicentre Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      STUDY AIM To decrease the number of breast cancer patients receiving overtreatment of the
      axilla, in order to positively influence the axillary morbidity rate and quality of life.

      PRIMARY OBJECTIVE To determine whether omitting completion axillary treatment is not inferior
      to the current axillary treatment regimen in sentinel node positive breast cancer patients
      undergoing a mastectomy, in terms of regional recurrence rate.

      HYPOTHESIS Completion axillary treatment can be safely omitted in sentinel node positive
      breast cancer patients undergoing a mastectomy. This will lead to a decreased axillary
      morbidity rate and to an increased quality of life, with non-inferior regional control,
      distant-disease free- and overall survival rates.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    slow accrual rate
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional recurrence rate</measure>
    <time_frame>up to ten years</time_frame>
    <description>Regional recurrence is defined as tumour recurrence and as residual tumour that became clinically apparent in ipsilateral axillary, infraclavicular and supraclavicular lymph nodes (pathologically proven).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Completion axillary treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Completion axillary treatment according to the Dutch breast cancer guideline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No completion axillary treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Completion axillary treatment</intervention_name>
    <description>Completion axillary treatment according to the Dutch breast cancer guideline</description>
    <arm_group_label>Completion axillary treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Aged 18 years or older

          -  Pathologically confirmed invasive unilateral breast carcinoma

          -  A clinical T1-2 tumour (including multifocal or multicentric breast cancer)

          -  Will be or is treated with mastectomy

          -  Clinically node negative: no signs of axillary lymph node metastases at physical
             examination and preoperative axillary ultrasound (or negative cyto-/histopathology)

          -  Sentinel lymph node procedure and its pathologic evaluation should be performed
             according to the Dutch breast cancer guideline

          -  pN1mi(sn) or pN1(sn): at least one and a maximum of three axillary sentinel lymph
             nodes containing micro- and/or macrometastases

          -  Written informed consent

        Exclusion Criteria:

          -  Clinically node positive pre-operative

          -  Sentinel lymph nodes only containing isolated tumour cells (&lt;0.2 mm)

          -  Solitary parasternal sentinel lymph node metastasis (pN1b)

          -  Bilateral breast cancer

          -  Irradical resection of primary tumour at time of randomization (applicable in case the
             mastectomy is performed before randomization)

          -  Evidence of metastatic disease

          -  History of invasive breast cancer

          -  Previous treatment of the axilla with surgery or radiotherapy (except surgery for
             hidradenitis suppurativa or for other superficially located skin lesions, such as
             naevi)

          -  Pregnant or nursing

          -  Other prior malignancies within the past 5 years (except successfully treated basal
             cell and squamous cell skin cancer, carcinoma in situ of the cervix or carcinoma in
             situ of the ipsilateral or contralateral breast) or unsuccessfully treated
             malignancies &gt; 5 years before randomization

          -  Unable or unwilling to give informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marjolein L Smidt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre+, Maastricht, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans JW de Wilt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Medical Centre, Nijmegen, the Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Centre+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuizen</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronovo / Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martini Ziekenhuis</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alrijne ziekenhuis</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud university medical center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurentius Ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Sneek</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rivierenland</name>
      <address>
        <city>Tiel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sentinel lymph node metastasis</keyword>
  <keyword>Completion axillary lymph node dissection</keyword>
  <keyword>Axillary radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

